Business News • PR NewsWire • AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress

AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS),...

View More : http://www.prnewswire.com/news-releases/abbvie-announces-late-breaking-results-from-phase-3-trial-of-humira-adalimumab-i...

Releted News by prnewswire

Infosys (NASDAQ: INFY) anuncia sus resultados para el trimestre finalizado el 30 de septiembre de 2014

Express Finance by DLL Delivers a Re-Imagined Sales Experience

Global Vacuum Pump Market Forecast and Opportunities, 2019 - Liquid Ring, Dry and Rotary Vane Vacuum Pumps

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress